Mumbai, April 16, 2018: Pharma Major, Alembic Pharma said that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) Acyclovir ointment USP, 5 per cent.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zovirax ointment 5 per cent, of Valeant Pharmaceuticals North America LLC. Acyclovir ointment USP 5 per cent, is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients.
Acyclovir, 5 per cent, have an estimated market size USD 145 million for twelve months ending December 2016 according to IMS. Alembic now has a total of 71 ANDA approvals (63 final approvals and 8 tentative approvals) from USFDA.
United News of India
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…